ATE252639T1 - Modifizierter, das dorsalgewebe beeinflussender faktor - Google Patents

Modifizierter, das dorsalgewebe beeinflussender faktor

Info

Publication number
ATE252639T1
ATE252639T1 AT98936850T AT98936850T ATE252639T1 AT E252639 T1 ATE252639 T1 AT E252639T1 AT 98936850 T AT98936850 T AT 98936850T AT 98936850 T AT98936850 T AT 98936850T AT E252639 T1 ATE252639 T1 AT E252639T1
Authority
AT
Austria
Prior art keywords
factor affecting
modified factor
dorsal tissue
muteins
dorsal
Prior art date
Application number
AT98936850T
Other languages
English (en)
Inventor
Neil Stahl
Richard M Harland
Aris N Economides
Original Assignee
Regeneron Pharma
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Univ California filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE252639T1 publication Critical patent/ATE252639T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98936850T 1997-07-17 1998-07-17 Modifizierter, das dorsalgewebe beeinflussender faktor ATE252639T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/897,236 US6075007A (en) 1997-07-17 1997-07-17 Modified noggin polypeptide and compositions
PCT/US1998/014603 WO1999003996A1 (en) 1997-07-17 1998-07-17 Modified dorsal tissue affecting factor and compositions

Publications (1)

Publication Number Publication Date
ATE252639T1 true ATE252639T1 (de) 2003-11-15

Family

ID=25407592

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98936850T ATE252639T1 (de) 1997-07-17 1998-07-17 Modifizierter, das dorsalgewebe beeinflussender faktor

Country Status (9)

Country Link
US (3) US6075007A (de)
EP (1) EP1003860B1 (de)
JP (1) JP4181300B2 (de)
AT (1) ATE252639T1 (de)
AU (1) AU735851B2 (de)
CA (1) CA2296769C (de)
DE (1) DE69819167T2 (de)
IL (2) IL134042A0 (de)
WO (1) WO1999003996A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141330A0 (en) 1998-08-20 2002-03-10 Regeneron Pharma Dcr5, a bmp-binding protein and aplications thereof
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
JP4813660B2 (ja) 1998-11-27 2011-11-09 ダーウィン ディスカバリー リミテッド 骨鉱化作用を増加するための組成物および方法
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
EP1357828A2 (de) * 2001-01-12 2003-11-05 University of Medicine and Dentistry of New Jersey Knochenmorphogenetisches protein-2 bei der behandlung und diagnose von krebs
US20020197648A1 (en) * 2001-05-02 2002-12-26 Silva Robin M. High throughput screening methods using magnetic resonance imaging agents
US20030134790A1 (en) * 2002-01-11 2003-07-17 University Of Medicine And Dentistry Of New Jersey Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
WO2003070189A2 (en) * 2002-02-15 2003-08-28 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
PT1608399E (pt) * 2003-03-14 2012-04-13 Ucb Mfg Inc Complexo de esclerostina e noguina ou cordina, e agentes que modulam a formação do referido complexo
US7381409B2 (en) 2003-06-16 2008-06-03 Celltech R&D, Inc. Antibodies specific for sclerostin and methods of screening and use therefor
EP1773986B1 (de) * 2004-07-09 2019-01-16 Viacyte, Inc. Präprimitivstreifen- und mesendoderm-zellen
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
AU2006289667A1 (en) * 2005-09-08 2007-03-15 Apollo Life Sciences Limited Noggin and chimeric molecules thereof
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
KR101163171B1 (ko) * 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
ES2849181T3 (es) 2009-04-22 2021-08-16 Viacyte Inc Composiciones celulares derivadas de células reprogramadas desdiferenciadas
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
EP2662385A4 (de) * 2011-01-07 2015-11-11 Chugai Pharmaceutical Co Ltd Verfahren zur verbesserung der physikalischen eigenschaften von antikörpern
EP2681242B1 (de) 2011-03-01 2018-01-24 Amgen Inc. Sclerostin- und dkk-1-bispezifische bindemittel
EP2688910B1 (de) 2011-03-25 2019-05-29 Amgen Inc. Anti-sclerostin-antikörperkristalle und formulierungen davon
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
SI2739311T1 (en) 2011-08-04 2018-07-31 Amgen Inc. Method for the treatment of bone defect defects
EP2797953B1 (de) 2011-12-28 2020-06-03 Amgen Inc. Verfahren zur behandlung von alveolarknochenverlust durch verwendung von anti-sclerostin-antikörpern
US9925260B2 (en) 2012-07-05 2018-03-27 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2016008975A1 (en) 2014-07-18 2016-01-21 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
HRP20260414T1 (hr) 2018-03-30 2026-05-08 Amgen Inc. C-terminalne varijante protutijela
EA202192305A1 (ru) * 2019-02-19 2021-12-08 Медицинише Универзитэт Вин Новая рекомбинантная диаминоксидаза и её применение для лечения заболеваний, характеризующихся избытком гистамина
JP7848994B2 (ja) * 2021-12-28 2026-04-21 国立大学法人山口大学 ノギンタンパク質を分泌する細胞およびそれを用いたオルガノイドの作製方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256568A (en) 1990-02-12 1993-10-26 Regeneron Phamaceuticals, Inc. Vectors and transformed most cells for recombinant protein production with reduced expression of selectable markers
EP0550665B1 (de) 1990-09-25 1996-07-31 Genentech, Inc. Neuer neurotropischer faktor
DK0662146T3 (da) * 1992-09-03 2000-11-13 Univ California Dorsalvævpåvirkende faktor og præparat
US5843775A (en) * 1992-09-03 1998-12-01 Regeneron Pharmaceuticals, Inc. Human dorsal tissue affecting factor (noggin) and nucleic acids encoding same

Also Published As

Publication number Publication date
AU735851B2 (en) 2001-07-19
WO1999003996A1 (en) 1999-01-28
EP1003860A1 (de) 2000-05-31
DE69819167T2 (de) 2004-07-22
JP2001510044A (ja) 2001-07-31
US6075007A (en) 2000-06-13
US6500640B1 (en) 2002-12-31
AU8570898A (en) 1999-02-10
IL134042A0 (en) 2001-04-30
JP4181300B2 (ja) 2008-11-12
CA2296769C (en) 2008-01-15
US20030129703A1 (en) 2003-07-10
HK1026229A1 (en) 2000-12-08
IL134042A (en) 2006-12-10
DE69819167D1 (de) 2003-11-27
CA2296769A1 (en) 1999-01-28
EP1003860B1 (de) 2003-10-22

Similar Documents

Publication Publication Date Title
DE69819167D1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
PT1091975E (pt) Nova ciclosporina com um perfil de actividade melhorado
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
IL106894A0 (en) Dorsal tissue affecting factor and compositions
DE69937573D1 (de) Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen
WO1999051731A3 (en) Maize histone deacetylases and their use
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
IT1293691B1 (it) Stent per angioplastica, particolarmente per il trattamento di vasi presentanti biforcazioni.
HUP0104825A3 (en) Genes and proteins, and their use
DE69532485D1 (de) Trehalose-freisetzendes Enzym, dafür kodierende DNA, Herstellung und Verwendung
EP1163373A4 (de) Antisense-modulation des zellulären hemmstoffs der apoptosis-expression
ATE291586T1 (de) Humanes antibiotisches protein
IL139604A0 (en) Novel peptides
BR0012043B1 (pt) composiÇço de tratamento de cabelo.
PE20399A1 (es) Muteina ob
DE69737265D1 (de) Herstellung nickelenthaltenden, gesinterten, verfestigten, feritischen rostfreien stahls
EP1096927A4 (de) Zusammensetzung für stressbehandlung
IT242987Y1 (it) Guarnitura per mobili.
DE10081621D2 (de) Promotorsystem, dessen Herstellung und Verwendung
DE69828906D1 (de) Herstellung von 1,3 propandiolestern
ITBO970602A0 (it) Apparecchiatura per trattamento di dialisi.
DE69823022D1 (de) Neues, menschliches tumorsuppressorgen.
GB9723824D0 (en) Cytostatic agents
NO179773C (no) Fjernbar, ortopedisk brudd-stabilisator

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1003860

Country of ref document: EP

REN Ceased due to non-payment of the annual fee